Malaria therapeutics: are we close enough?

H Tripathi, P Bhalerao, S Singh, H Arya, BS Alotaibi… - Parasites & …, 2023 - Springer
Malaria is a vector-borne parasitic disease caused by the apicomplexan protozoan parasite
Plasmodium. Malaria is a significant health problem and the leading cause of …

The metabolic advantage of tumor cells

M Israël, L Schwartz - Molecular cancer, 2011 - Springer
Oncogenes express proteins of" Tyrosine kinase receptor pathways", a receptor family
including insulin or IGF-Growth Hormone receptors. Other oncogenes alter the PP2A …

Antimalarial activity of small-molecule benzothiazole hydrazones

S Sarkar, AA Siddiqui, SJ Saha, R De… - Antimicrobial agents …, 2016 - Am Soc Microbiol
We synthesized a new series of conjugated hydrazones that were found to be active against
malaria parasite in vitro, as well as in vivo in a murine model. These hydrazones …

Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis

C Huthmacher, A Hoppe, S Bulik, HG Holzhütter - BMC systems biology, 2010 - Springer
Background Despite enormous efforts to combat malaria the disease still afflicts up to half a
billion people each year of which more than one million die. Currently no approved vaccine …

[HTML][HTML] A Plasmodium falciparum lysophospholipase regulates host fatty acid flux via parasite lipid storage to enable controlled asexual schizogony

PK Sheokand, Y Yamaryo-Botté, M Narwal, CS Arnold… - Cell Reports, 2023 - cell.com
Phospholipid metabolism is crucial for membrane biogenesis and homeostasis of
Plasmodium falciparum. To generate such phospholipids, the parasite extensively …

MDN-0104, an Antiplasmodial Betaine Lipid from Heterospora chenopodii

J Martin, G Crespo, V Gonzalez-Menendez… - Journal of natural …, 2014 - ACS Publications
Bioassay-guided fractionation of the crude fermentation extract of Heterospora chenopodii
led to the isolation of a novel monoacylglyceryltrimethylhomoserine (1). The structure of this …

Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system

Y Osorio, BL Travi, AR Renslo… - PLoS neglected …, 2011 - journals.plos.org
Background New drugs are needed to treat visceral leishmaniasis (VL) because the current
therapies are toxic, expensive, and parasite resistance may weaken drug efficacy. We …

Structure-based virtual screening approach reveals natural multi-target compounds for the development of antimalarial drugs to combat drug resistance

B Naik, N Gupta, P Godara, V Srivastava… - Journal of …, 2023 - Taylor & Francis
Compared to the previous year, there has been an increase of nearly 2 million malaria
cases in 2021. The emergence of drug-resistant strains of Plasmodium falciparum, the most …

Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds

GJ Crowther, AJ Napuli, JH Gilligan, K Gagaring… - Molecular and …, 2011 - Elsevier
The efficacy of most marketed antimalarial drugs has been compromised by evolution of
parasite resistance, underscoring an urgent need to find new drugs with new mechanisms of …

Identification and molecular characterization of an Alba-family protein from human malaria parasite Plasmodium falciparum

M Goyal, A Alam, MS Iqbal, S Dey, S Bindu… - Nucleic acids …, 2012 - academic.oup.com
We have investigated the DNA-binding nature as well as the function of a putative Alba
(Acetylation lowers binding affinity) family protein (PfAlba3) from Plasmodium falciparum …